Довготривала ефективність радіочастотної денервації ниркових артерій у пацієнтів з резистентною артеріальною гіпертензією (результати 10-річного спостереження)

О.Л. Рековець, Ю.М. Сіренко, О.О. Торбас, С.М. Кушнір, Г.Ф. Примак

Література

1. Dobrokhod H.S. Own Experience of Patient Selection for Renal Denervation. Arterialʹna hipertenziya. 2014. № 3. S. 45–48. DOI:10.22141/2224-1485.3.35.2014.82720.
2. Azizi M, Steichen O, Frank M, Bobrie G, Plouin PF, Sapoval M. Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. Eur J Vasc Endovasc Surg. 2012;43(3):293-9. doi: 10.1016/j.ejvs.2011.11.022. Epub 2012 Jan 9. PMID: 22237510.
3. Banegas JR, Messerli FH, Waeber B, Rodríguez-Artalejo F, de la Sierra A, Segura J, Roca-Cusachs A, Aranda P, Ruilope LM. Discrepancies between office and ambulatory blood pressure: clinical implications. Am J Med. 2009;122(12):1136-41. doi: 10.1016/j.amjmed.2009.05.020. PMID: 19958892.
4. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-401. doi:10.1056/NEJMoa1402670. Epub 2014 Mar 29. PMID: 24678939.
5. Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O’Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64(11):1071-8. doi:10.1016/j.jacc.2014.05.012. Epub 2014 May 20. PMID: 24858423.
6. Böhm M, Linz D, Urban D, Mahfoud F, Ukena C. Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol. 2013;10(8):465-76. doi:10.1038/nrcardio.2013.89. Epub 2013 Jun 18. PMID: 23774592.
7. Böhm M, Linz D, Ukena C, Esler M, Mahfoud F. Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond? Circ Res. 2014;115(3):400-9. doi:10.1161/CIRCRESAHA.115.302522. PMID: 25035133.
8. Burton RF. Estimating body surface area from mass and height: theory and the formula of Du Bois and Du Bois. Ann Hum Biol. 2008;35(2):170-84. doi:10.1080/03014460801908439. PMID: 18428011.
9. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403-19. doi:10.1161/HYPERTENSIONAHA.108.189141. Epub 2008 Apr 7. PMID: 18391085.
10. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R245-53. doi:10.1152/ajpregu.00647.2009. Epub 2009 Dec 2. PMID: 19955493.
11. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046-58. doi:10.1161/CIRCULATIONAHA.111.030189. Epub 2011 Aug 8. PMID: 21824920; PMCID: PMC3210066.
12. Hayek SS, Abdou MH, Demoss BD, Legaspi JM, Veledar E, Deka A, Krishnan SK, Wilmot KA, Patel AD, Kumar VR, Devireddy CM. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients. Am J Hypertens. 2013;26(12):1452-8. doi:10.1093/ajh/hpt132. Epub 2013 Aug 9. PMID: 23934709.
13. Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I, Strandgaard S. The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond). 1994;87(1):13-20. doi:10.1042/cs0870013. PMID: 8062514.
14. Kannan S, Mahadevan S, Ramji B, Jayapaul M, Kumaravel V. LDL-cholesterol: Friedewald calculated versus direct measurement-study from a large Indian laboratory database. Indian J Endocrinol Metab. 2014;18(4):502-4. doi:10.4103/2230-8210.137496. PMID: 25143906; PMCID: PMC4138905.
15. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275-81. doi:10.1016/S0140-6736(09)60566-3. Epub 2009 Mar 28. PMID: 19332353.
16. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C; European Society of Hypertension. Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention. 2013;9 Suppl R:R58-66. doi:10.4244/EIJV9SRA11. PMID: 23732157.
17. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Böhm M. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60(2):419-24. doi:10.1161/HYPERTENSIONAHA.112.193870. Epub 2012 Jun 25. PMID: 22733462.
18. Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Worthley MI, Worthley SG. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension. 2014;64(3):565-72. doi:10.1161/HYPERTENSIONAHA.114.03605. Epub 2014 Jun 16. PMID: 24935940.
19. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54(6):1195-201. doi:10.1161/HYPERTENSIONAHA.109.138610. Epub 2009 Oct 12. PMID: 19822798.
20. Schuck O, Marusova L, Lanska V. Moznosti vyuzití vzorce Cocrofta a Gaulta pro posouzení 24hodinového mocového vylucování elektrolytů [Use of the Cocroft and Gault formula for evaluation of 24-hour urinary excretion of electrolytes]. Bratisl Lek Listy. 1999;100(8):422-5. Czech. PMID: 10645029.
21. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-7. doi:10.1161/HYPERTENSIONAHA.110.163014. Epub 2011 Mar 14. PMID: 21403086.
22. Symplicity HTN-2 Investigators; Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-9. doi:10.1016/S0140-6736(10)62039-9. Epub 2010 Nov 17. PMID: 21093036.
23. Stea F, Bozec E, Millasseau S, Khettab H, Boutouyrie P, Laurent S. Comparison of the Complior Analyse device with Sphygmocor and Complior SP for pulse wave velocity and central pressure assessment. J Hypertens. 2014;32(4):873-80. doi:10.1097/HJH.0000000000000091. PMID: 24509122.
24. Zhang Y, Zhang X, Liu L, Zanchetti A; FEVER Study Group. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32(12):1500-8. doi:10.1093/eurheartj/ehr039. Epub 2011 Feb 22. PMID: 21345850.
25. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34(28):2132-40. doi:10.1093/eurheartj/eht197. Epub 2013 Jun 19. PMID: 23782649; PMCID: PMC3717311.